Abstract 103P
Background
Microsatellite instability (MSI) is a powerful predictor for the efficacy of immune checkpoint inhibitor (ICI) therapy across tumor types. Although conventional MSI testing strategies are widely used, NGS represents a promising tool for MSI detection. We have developed and validated the NGS test system for MSI detection in solid tumors.
Methods
The following sample types were selected for validation of our test system: G1 - archive FFPE tumor samples collected from patients with known MSI status; G2 - archive paired (FFPE/ctDNA) samples collected from patients with tumors where MSI is uncommon (<1%); G3 - paired (FFPE/ctDNA) MSI+ samples. All FFPE samples were tested using the gold standard (5-loci PCR, 4-antibody IHC). Samples were considered MSI+ if PCR or IHC were positive; MSI- when both were negative. Detection of MSI was performed using k-mer distributions of 28 loci.
Results
A total of 123 samples for 109 patients were analyzed - 77 (62.6%) FFPE, 46 (37.4%) ctDNA; 6 patients had paired samples. A total of 30 (FFPE, 83% CRC), 72 (41 FFPE, 31 ctDNA; 62.3% NSCLC) and 21 (6 patients; 6 FFPE, 15 ctDNA; 66.7% CRC) were selected for G1, G2 and G3, respectively. Rate of agreement (κ) between NGS and gold standard in G1 was 0.8 (95% CI, 0.58-1) [κ for NGS/PCR 0.93 (95% CI, 0.8-1)], and 1 in G3. In G2, 100% of samples were MSS following NGS. In G3, for all 6 samples there were no disagreements between NGS and gold standard. Across all analyzed FFPE samples, κ between NGS and gold standard was 0.9 (95% CI 0.88-0.92). When comparing results of PCR and IHC (FFPE samples), low concordance was noted (κ=0.5, 95% CI, 0.22-0.78). High concordance was observed between PCR and NGS (κ=0.94, 95% CI, 0.83-1). Concordance of IHC and NGS was low (κ=0.55, 95% CI, 0.28-0.83). Sensitivity / specificity of NGS vs IHC in detecting MSI were 76.2% / 80%. Sensitivity / specificity of NGS vs PCR were 95.5% / 100%. Sensitivity / specificity of NGS in detecting MSI using ctDNA vs FFPE were 100% / 100%.
Conclusions
Low concordance was observed between IHC and PCR for MSI detection (κ=0.5, 95% CI, 0.22-0.78). Concordance of PCR and NGS was high (κ=0.94, 95% CI, 0.83-1); concordance between IHC and NGS was lower (κ=0.55, 95% CI, 0.28-0.83). Sensitivity of MSI detection using ctDNA was 100%.
Editorial acknowledgement
Clinical trial identification
Legal entity responsible for the study
The authors.
Funding
This study was supported by Russian Science Foundation (grant № 22-75-10154).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
114P - Circulating microRNAs and response to oncological and surgical therapy in patients with locally advanced gastric cancer
Presenter: Vasileia Kokala-Dimitropoulou
Session: Cocktail & Poster Display session
Resources:
Abstract
115P - BrainStorm-NSE: Serum neuron-specific enolase as a biomarker for central nervous system metastases: A prospective cohort study
Presenter: Diogo Martins-Branco
Session: Cocktail & Poster Display session
Resources:
Abstract
116P - Switching to a multigenic parallel sequencing approach: The landscape of biomarkers profiling changing between immunohistochemistry and next generation sequencing advantages and sustainability from a public hospital in Northern Italy
Presenter: Giulia Ghirardi
Session: Cocktail & Poster Display session
Resources:
Abstract
117P - Homologous recombination deficiency (HRD) by shallow whole genome sequencing (sWGS): Seamless integration in an existing NGS somatic oncology workflow
Presenter: Etienne Muller
Session: Cocktail & Poster Display session
Resources:
Abstract
118P - Molecular diagnostics of gastrointestinal stromal tumors in the era of precision oncology
Presenter: Alena Kalfusova
Session: Cocktail & Poster Display session
Resources:
Abstract
119P - De novo and histologically transformed small-cell lung cancer is sensitive to lurbinectedin treatment through the modulation of EMT and NOTCH signaling pathways
Presenter: Triparna Sen
Session: Cocktail & Poster Display session
Resources:
Abstract
120P - Anti-angiogenic therapy or immunotherapy? A multicenter real-world study of patients with advanced non-small cell lung cancer with EGFR / HER2 exon 20 insertion mutations
Presenter: Tianqing Chu
Session: Cocktail & Poster Display session
Resources:
Abstract
121P - Clinical outcomes of compound EGFR mutation in non-small cell lung cancer: A national, retrospective, multicenter study
Presenter: Aurélien Brindel
Session: Cocktail & Poster Display session
Resources:
Abstract
122P - Molecular testing, treatment, and response of patients with advanced solid tumors harboring an NTRK gene fusion: Second interim results of the REALTRK registry
Presenter: Sebastian Lange
Session: Cocktail & Poster Display session
Resources:
Abstract
123P - Incidence and outcomes of anaplastic lymphoma kinase (ALK) and ROS 1 positive advanced NSCLC: A real world experience
Presenter: Stalin Chowdary Bala
Session: Cocktail & Poster Display session
Resources:
Abstract